Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.

Saved in:
Bibliographic Details
Title: Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.
Authors: van der Schalk TE; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Berkell M; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium., Hottebeekx A; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium., Timbermont L; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Tabor DE; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Lammens C; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Recanatini C; Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases Group, University Medical Center Utrecht, Utrecht, The Netherlands., Ruzin A; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., DiGiandomenico A; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Jafri H; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Chastre J; Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Esser MT; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., François B; ICU department and Inserm CIC 1435 & UMR 1092, CHU Limoges, Limoges, France., Bonten MJM; Julius Center for Health Sciences and Primary Care, Epidemiology of Infectious Diseases Group, University Medical Center Utrecht, Utrecht, The Netherlands., Goossens H; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Kluytmans JAJW; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Oliver A; Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, CIBERINFEC, Palma de Mallorca, Spain., Glupczynski Y; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium., Kumar-Singh S; Molecular Pathology Group, Cell Biology & Histology, University, of Antwerp, Wilrijk, Belgium., Malhotra-Kumar S; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium. surbhi.malhotra@uantwerpen.be.
Corporate Authors: ASPIRE-ICU study team, COMBACTE-MAGNET EVADE study group
Source: Npj antimicrobials and resistance [NPJ Antimicrob Resist] 2026 May 08; Vol. 4 (1). Date of Electronic Publication: 2026 May 08.
Publication Type: Journal Article
Journal Info: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918804282606676 Publication Model: Electronic Cited Medium: Internet ISSN: 2731-8745 (Electronic) Linking ISSN: 27318745 NLM ISO Abbreviation: NPJ Antimicrob Resist Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2731-8745
DOI:10.1038/s44259-026-00199-3